Replies to post #756003 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

So are you brave enough to say above quotes by you were pure speculation and BS 

[GoodGuyBill]

Much ado about nothing....

This is what I said (as you quoted): "DCVax works, targeting all tumor-based cancers, is highly scalable, and is extensively protected by patents." Is this not true, please explain?!

DCVax has demonstrated promising results in glioblastoma (nGBM and rGBM) through its Phase 3 trial, as published in JAMA Oncology. DCVax's mechanism of action is to prep/leverage dendritic cells to stimulate the immune system to attack cancer tumor antigens. The same antigens in nGBM/rGBM are in other cancer tumors. We know this to be true. So why do I need to give you statistical evidence for MHRA RGBM/nGBM approval?

Furthermore, I stated,

While the current approval focus is on GBM, the platform's mechanism—leveraging dendritic cells to stimulate the immune system to attack all antigens that make up a cancer tumor—has the potential to target all tumor-based cancers due to shared antigens. Its application to other cancers may require further validation, but this broader potential could explain the delay, as NWBO could be pursuing a cancer-agnostic designation for DCVax, as some posters speculate (did you know NWBO was pursuing an expansion to treat rGBM or the SAP consisted of 1.7 million pages, if memory serves me correctly?).

What are you arguing about? Do you know, lol?